By IANS,
New Delhi : The following is a fact sheet on Ranbaxy Laboratories Ltd, India’s largest pharmaceuticals company, which will now become a subsidiary of Daiichi Sankyo of Japan after a $4.6 billion deal announced Wednesday.
Founder: Late Bhai Mohan Singh
Incorporation: 1961 (public issue in 1973)
Initiator of globalisation: Late Parvinder Singh (son of founder)
Managing director and chief executive: Malvinder Mohan Singh (son of Parvinder Singh)
Non-executive chairman: Harpal Singh
Turnover: $1.62 billion in 2007
Domestic sales: $301 million in 2007
Largest market: North America, contributing 26 percent of sales
Positioning in India: Largest drugs maker in $7.3 billion industry
Global positioning: Ranked among top 10 global generic drug companies
Global footprint: Presence in 23 of the top 25 global drugs markets
Manufacturing: Facilities in 11 countries
Subsidiaries: Fortis Healthcare, Religare, Ranbaxy Pharmaceuticals
Areas of strength: Generic, out-of-patent, drugs
New initiatives: Oncology, Peptides and Limuses
Current stock price: Rs.592 per share (face vale Rs.5)
Prompters’ stake: 34.8 percent (valued at $2.4 billion)
Valuation after Daiichi Sankyo deal: $8.9 billion
Low point: Ownership battle between Bhai Mohan Singh and Parvinder Singh in early 1990s
High points: Acquistion of Terpia of Romania for $324 million; acquisition of Be Tabs of South Africa for $70 million